TABLE 2.
Effect of administration of LP202195 with or without FOS on the absolute abundance of LP202195 in stool samples collected post-intervention (days 14 to 60), relative to placebo or LP7 + FOS, and relative risk of high abundancea
| Parameter | Intervention group | ||||
|---|---|---|---|---|---|
| Placebo | LP1 | LP1 + FOS | LP7 | LP7 + FOS | |
| Number of samples, N | 278 | 267 | 280 | 296 | 272 |
| AAPost(14-60) of LP202195 (log10 cells/µg DNA), mean ± SE | 1.86 ± 0.03 | 2.38 ± 0.05 | 2.58 ± 0.07 | 3.09 ± 0.07 | 3.15 ± 0.06 |
| Mean difference, relative to placebo, in AA of LP202195 (log10 cells/µg DNA), (95% CI) | Ref | 0.53 (0.41, 0.65) | 0.73 (0.59, 0.88) | 1.24 (1.09, 1.38) | 1.30 (1.16, 1.43) |
| Mean difference, relative to LP7 + FOS, in AA of LP202195 (log10 cells/µg DNA), (95% CI) | NA | −0.77 (−0.93, –0.60) | −0.56 (−0.74, –0.38) | −0.06 (−0.24, 0.12) | Ref |
| Samples in low abundance group (i.e., AA < 3 log10 cells/µg DNA), n (%) | 269 (97) | 204 (76) | 203 (72) | 167 (56) | 139 (51) |
| Samples in high abundance group (i.e., AA ≥ 3 log10 cells/ µg DNA), n (%) |
9 (3.2) | 63 (24) | 77 (28) | 129 (44) | 133 (49) |
| Relative risk (RR) of high (vs low) abundance, relative to placebo (95% CI) | Ref | 7.1 (4.3, 11.9) | 8.3 (5.0, 13.7) | 13.4 (8.2, 22.0) | 14.2 (8.7, 23.3) |
a
AA, absolute abundance; NA, not applicable.